<DOC>
	<DOCNO>NCT00669786</DOCNO>
	<brief_summary>A randomize control trial compare ongoing pregnancy rate ( primary end-point ) 280 patient undergoing IVF/ICSI stimulation hp-hMG rFSH control GnRH antagonist . Non significant difference observe hp-hMG rFSH term ongoing pregnancy rate per start cycle ( 35.0 % vs. 32.1 % ; p=0.61 ) ; R.R : 1.09 ( 95 % CI : 0.78-1.51 ; Risk Difference : 2.9 % ) . No difference observe implantation , clinical pregnancy pregnancy loss rate . Patients receive rFSH obtain oocyte ( 14.4 ± 8.1 vs. 11.3 ± 6.0 ; p=0.001 ) . Estradiol high end stimulation hp-hMG group , Progesterone high patient stimulate rFSH .</brief_summary>
	<brief_title>Human Menopausal Gonadotropin ( HMG ) v Recombinant Follicle Stimulating Hormone ( rFSH ) Gonadotropin Releasing Hormone ( GnRH ) Antagonist Cycles</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<mesh_term>Menotropins</mesh_term>
	<criteria>woman good physical mental health age 1837 year regular menstrual cycle range 25 35 day ; body mass index ( BMI ) &lt; 30 kg/m2 normal basal serum FSH ( ≤ 10 IU/L ) E2 ( ≤ 75 pg/mL ) level determine day 3 cycle previous COH uterine ( fibroid , adenomyosis , mullerian malformation ) , ovarian ( endometrioma , polycystic ovary ) adnexa ( hydrosalpinx ) abnormality assess vaginal ultrasound . patient history recurrent pregnancy loss significant systemic disease , endocrine metabolic disorder concomitant medication interfering purpose study patient receive ovulation induction drug within one month inclusion study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>37 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Ongoing Pregnancy Rate</keyword>
</DOC>